In the News

1852 News Items found
MSK myeloma specialist and cellular therapist Saad Usmani, MD
Article
Read about a new treatment combining bispecific antibodies that is effective against extramedullary myeloma.
Michael with his granddaughter on a boat
A phase 3 trial led by MSK showed that adding epcoritamab to traditional treatment for follicular lymphoma benefits patients. Epcoritamab received FDA approval based on the findings.
MSK breast cancer patient Majiel Baker is seen at the beach with her husband and children.
Learn why over 5,000 people a year travel more than 150 miles to MSK for cancer care, including resources for the specific needs of traveling patients and their loved ones.
Dr. Omar Abdel-Wahab in his lab
Q&A
A leader in developing better treatments for a range of blood cancers, Dr. Omar Abdel-Wahab is only the second person from MSK to receive the Paul Marks Prize for Cancer Research. 
Jack Georgakis is seen wrestling in a martial arts class.
Learn about a new approach helping to reduce the risk of stomach and esophageal cancer coming back after surgery, which has been approved by the FDA thanks to a clinical trial with immunotherapy led by researchers at MSK.
MSK patient Karren Tyler poses in front of a portrait of two dogs
Thanks to a second opinion and minimally invasive surgery at MSK to remove tongue cancer, Karren Tyler is back home in Charlottesville, Virginia, cancer free and focused on giving back to other cancer patients.
Dr. Charles Rudin
The U.S. Food and Drug Administration (FDA) has granted full approval to the drug tarlatamab, a bispecific T cell engager, for small cell lung cancer, based on results from a phase 3 clinical trial led by Dr. Charles Rudin at MSK.
Man with gray hair sits in a doctor's office looking worried
Feature
How To Stop the Fear of Cancer
Learn more about five essential strategies for coping with the fear of cancer, from MSK psychiatrist Dr. Monique James.
Lab coat with the MSK logo hangs in a lab
MSK Research Highlights, November 20, 2025
New MSK research finds a potential therapeutic opportunity in regulatory T cells’ resilience to the loss of Foxp3; shows how cancer develops resistance to antibody-drug conjugates; develops a new system to help make gene editing safer and more reliable; and shows provider billing margin doesn’t drive cancer treatment selection.
A researcher points to cells on a screen
In 2025, MSK was again ranked among the top organizations with the greatest number of highly cited scientific researchers worldwide, according to the annual list of Highly Cited Researchers, published by the Institute for Scientific Information at Clarivate.